At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Lenalidomide, and 1 other intervention for Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma and 11 related conditions. Completed, enrolled 66 participants across 91 sites.
Detailed Summary
This phase II trial studies how well lenalidomide and rituximab work in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide together with rituximab may kill more cancer cells.
Study Details
Timeline
Interventions
Correlative studies
Given PO
Given IV